Benedek-Jaszmann L J, Hearn-Sturtevant M D
Lancet. 1976 May 22;1(7969):1095-8. doi: 10.1016/s0140-6736(76)90062-3.
17 women with premenstrual symptoms received bromocriptine (CB 154) and placebo in a double-blind crossover manner. 5 because pregnant and 10 who completed 2 cycles showed significant improvement in breast symptoms, oedema, weight gain, and mood with bromocriptine. Prolactin concentrations were suppressed. In 34 women with premenstrual symptoms, who had been warned of possible increased fertility, bromocriptine 2-5 mg twice daily from the 10th day of the menstrual cycle for 1--11 months gave marked or complete relief. 45 women attending the infertility clinic took 2-5 mg bromocriptine twice daily for 186 cycles; 23 became pregnant, 2 had marked relief and 20 complete relief from premenstrual symptoms. The relief of premenstrual symptoms by bromocriptine may be due to suppression of prolactin concentrations, which may be a major factor in premenstrual syndrome.
17名有经前症状的女性以双盲交叉方式接受了溴隐亭（CB 154）和安慰剂治疗。5名怀孕，10名完成两个周期治疗的女性在使用溴隐亭后，乳房症状、水肿、体重增加和情绪方面有显著改善。催乳素浓度受到抑制。在34名有经前症状且已被告知可能增加受孕几率的女性中，从月经周期第10天开始，每天两次服用2 - 5毫克溴隐亭，持续1 - 11个月，症状得到明显或完全缓解。45名在不孕诊所就诊的女性每天两次服用2 - 5毫克溴隐亭，共进行了186个周期的治疗；23名怀孕，2名经前症状明显缓解，20名完全缓解。溴隐亭缓解经前症状可能是由于抑制了催乳素浓度，而催乳素浓度可能是经前综合征的一个主要因素。
